AbbVie closes USD 10B multi-tranche senior notes offering to fund Apogee deal

• AbbVie completed a USD 10 billion senior notes offering, including senior floating rate notes due 2028.
• Deal included fixed-rate senior notes across eight maturities from 2028 to 2066, with coupons from 4.5% to 6.1%.
• Proceeds earmarked to fund part of the cash consideration for AbbVie’s planned acquisition of Apogee Therapeutics.
• If the Apogee deal is terminated, AbbVie must redeem the floating-rate notes and fixed-rate notes due 2028-2038 at 101%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-098367), on August 18, 2026, and is solely responsible for the information contained therein.